STAT+: Pharmalittle: We’re reading about the FDA warning Novo Nordisk, Lilly investing in China, and more
Stat News • 3/11/2026
Summary
The Trump administration's push for lower U.S. drug prices assisted Astellas in obtaining higher pricing for its new eye medicine in Japan. The news also includes an FDA warning regarding Novo Nordisk and mentions Lilly's investments in China.
Advertisement
Lindy Score Breakdown (V4.2)
5h
Age
1
Sources
from cluster
13
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier83% (0.5^13/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about a U.S. senator probing FDA, BioNTech founders leaving, and much more
Stat News • 1 day ago
STAT+: Novo Nordisk is warned by the FDA for failing to report side effects
Stat News • 1 day ago
STAT+: Pharmalot: We’re reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more
Stat News • 2 days ago
STAT+: FDA approves leucovorin for rare disorder without trial data
Stat News • Today
STAT+: BioNTech founders to depart, form new mRNA-focused company
Stat News • 1 day ago
STAT+: What’s next for RFK Jr.’s MAHA allies on vaccine policy?
Stat News • 1 day ago
STAT+: New nonprofit launches with at least $500 million to modernize scientific process for AI era
Stat News • Today
STAT+: This billionaire wants to make science better, especially for AI
Stat News • Today
STAT+: After UnitedHealth moved in, Oregon sought to rein in corporate health care. Now, it’s facing an early test
Stat News • 2 days ago
STAT+: As controversial decisions mount, FDA shuns public advisory meetings
Stat News • 2 days ago